25th Workshop on Methods in Clinical Cancer Research 2025
14 – 20 June 2025
Related Articles
PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors
Glenn J. Hanna, MD, discusses data with PYX-201, expanding on the phase 1 trial which evaluated the agent in head and neck squamous cell carcinoma.
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for…
The REST study: isatuximab-bortezomib-lenalidomide in elderly patients with myeloma
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, provides insight into the REST study (NCT04939844) and comments on what the results demonstrate about the…
Targeted anti-cancer agents and risk of venous thromboembolism
The incidence of one-year venous thromboembolism (VTE) after cancer diagnosis is reported to be increasing for several types of cancer. The introduction of targeted anti-cancer…
Liquid biopsies to tailor immunotherapy: New peomising data
Studies explore the prognostic & predictive values of ctDNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer
CRB-701 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.
Myeloid effector cells in cancer
Schol et al. describe in this perspective the key role of myeloid effector cells in tumor control during successful immunotherapy. They also discuss myeloid cell tumor-rejecting…
FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL
A sBLA has been accepted for review seeking the approval of glofitamab plus gemcitabine and oxaliplatin for pretreated, transplant-ineligible patients with relapsed/refractory DLBCL.
FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer
The FDA granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.
Immediate Surgery Can Improve Long-Term Outcomes in Older Breast Cancer Patients
Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.
